Palvella Therapeutics (PI6) Q2 2026 Earnings Report

The call highlights substantial clinical and regulatory progress—compelling Phase III SELVA results (95% improvement on primary endpoint), rolling review and first NDA module submission—supported by strong financial resources (~$251M cash) and accelerated commercial hiring (≈40 reps). Near-term risks include the need to complete the NDA, initial lack of Breakthrough for cVM (to be addressed with additional 24‑week data and qualitative evidence), increased 2026 cash spend to accelerate launch readiness, and multi-year timelines to expand indications beyond microcystic LMs. Overall, the positive clinical data, regulatory momentum, funding and clear commercial plan meaningfully outweigh the challenges and remaining execution risks.

Palvella reiterated clear near-term regulatory and commercial guidance: rolling review granted and first NDA module submitted, with full NDA submission on track in H2 2026 and potential FDA approval in H1 2027; Phase III SELVA met its primary, key secondary and all four prespecified secondary endpoints (95% of patients improved on the primary at week 24; blinded mean mLM‑MCSS improved 3.4 points — 48% of maximum — and run‑in change was −0.1), the pediatric 6–11 cohort showed a mean mLM‑IGA improvement of 2.46 with 100% rated much/very much improved and all electing extension. Other program metrics: TOIVA (cVM) Phase II showed 73% responders and a Phase III start is planned in Q4 2026 (modeling a potential cVM approval in 2029); angiokeratoma LOTU Phase II (up to 15 patients) dosed in April with data expected H2 2027; DSAP Q2 Phase II planned (~15 patients) for Q4 2026. Epidemiology and commercial sizing: conservative U.S. diagnosed estimates >30,000 MLM (claims 45k–95k), >75,000 cVM (literature ~135k), >50,000 angiokeratomas, >50,000 DSAP — with potential addressable population >300,000 across indications. Commercial and financial guidance: ~$251M cash at 6/30/26 after a $230M Feb raise (original target $150M), 2026 cash spend ~$85–95M, launch field force ~40 reps (engaged >200 of 400 target clinics to date), pump covers up to 200 cm2 per actuation (30‑day supply), pricing guidance $100k–$200k/pt/yr, and regulatory pathways include Breakthrough/Fast Track/Orphan/Orphan Grant and a 505(b)(2) strategy.